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Summary 
Apoptosis occurs in the normal liver and in various forms of  liver disease. The CD95 (APO-1/ 
Fas) (CD95) receptor mediates apoptosis, and liver cells in animal models are acutely sensitive 
to apoptosis initiated by this receptor. We have used primary human hepatocytes as a model 
system to investigate CD95-mediated apoptotic liver damage. Treatment of fresh human hepa- 
tocytes with low concentrations of agonistic antibodies against  CD95 resulted in apoptosis of 
>95% of the cultured liver cells within 4 and 7.5 h. Immunohistology of a panel of explanted 
liver tissues revealed that hepatocytes in normal livers (n =  5) and in alcoholic cirrhosis (n -- 
13) expressed low constitutive levels of CD95. CD95 receptor expression was highly elevated 
in hepatocytes in hepatitis B virus-related cirrhosis (n =  9) and in acute liver failure (n =  8). By 
in situ hybridization CD95 ligand messenger R.NA expression was  absent in normal liver but 
detected at high levels in livers with ongoing liver damage. In cases of hepatitis B virus-related 
cirrhosis and acute hepatic failure, ligand expression was found primarily in areas with lympho- 
cytic infiltration. In contrast, in patients with alcoholic liver damage, high CD95 ligand mes- 
senger R.NA expression was found in hepatocytes. These findings suggest that liver destruction 
in hepatitis B may primarily involve killing of hepatocytes by T lymphocytes using the CD95 
receptor-ligand system. In alcoholic liver damage, death of hepatocytes might occur by fratri- 
cide and paracrine or autocrine mechanisms mediated by the hepatocytes themselves. 
p roliferation and apoptosis of cells play an essential  role 
in  development  and  homeostasis  of multicellular  or- 
ganisms  (for review see references 1 and 2). Thus, apoptosis 
is found in the metamorphosis of the tadpole and in the de- 
velopment of the nervous and of the immune system, for 
example  (3-5).  Apoptosis  may  also  serve  as  a  defense 
against  viral invasion.  Certain viral infections lead  to  the 
initiation of an intrinsic death program (6-8), which spares 
other cells of the same organism from subsequent infection. 
In addition,  cytotoxic T  lymphocytes and NK cells elimi- 
nate their targets by apoptosis (9-13). 
Apoptosis is  mediated through activation of the  CD95 
receptor system.  CD95,  a member of the TNF receptor/ 
nerve growth factor receptor family is a type I transmem- 
brahe protein (14), and it acts as an inducer of apoptosis in 
CD95-expressing cells  in response to  agonistic  antibodies 
or ligand binding (15-19).  The ligand for CD95 has been 
recently cloned and found to be a type II transmembrane 
protein that belongs to the TNF family. The ligand is ex- 
pressed in various cells, including activated thymocytes and 
splenocytes, as well as in the testis,  lung,  and kidney (20, 
21). The CD95 receptor-ligand system plays an important 
role in B  and T  lymphocyte development and maturation 
(5). In addition, the CD95 and the perforin system mediate 
T  cell cytotoxicity (10-12, 22-27).  CD95 is constitutively 
expressed in a wide range of tissues  (28). Therefore, it may 
have  a  general biological role beyond its  function in  the 
immune system. 
Many nonlymphoid tissues,  such as liver, are CD95  re- 
ceptor positive. The liver is highly sensitive to induction of 
apoptosis by the agonistic anti-Fas antibody. Mice injected 
intraperitoneally  with  10-100  I*g  anti-Fas  died  rapidly, 
within  several  hours  (29).  Biochemical,  histological,  and 
electron  microscopic  analysis  revealed  that  severe  liver 
damage  by apoptosis was  the  most likely cause  of death. 
These findings suggest that CD95 is involved in apoptosis 
in the liver, and they pose the question of whether CD95- 
mediated cell death plays a role in liver failure in humans. 
Apoptosis has been demonstrated in the acinar zone 3 of 
the liver as a mechanism to eliminate senescent hepatocytes 
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course  of liver  regeneration  or  during  involution  of the 
liver after cessation of treatment with lipophilic compounds 
such  as phenobarbital, which  initially caused  hypertrophy 
and hyperplasia of this organ (1). Furthermore, apoptosis in 
the  liver has  been  observed during viral infection  (1,  8). 
Councilman bodies, a characteristic pathological feature in 
viral hepatitis, closely resemble apoptotic cells or fragments. 
During viral hepatitis, activated T  cells attack hepatocytes 
(31).  The  CD95  ligand  (CD95L) 1 is  expressed  in  T  cells 
upon  activation,  and  the  CD95  receptor  is  constitutively 
expressed  in  liver  cells  (28).  Therefore,  activated T  cells 
might kill hepatitis B virus (HBV) antigen-expressing hepa- 
tocytes  by  CD95  ligand-receptor  interaction  and,  thus, 
clear HBV from the liver. Since HBV-infected individuals 
can either become chronic virus carriers or can clear the vi- 
rus,  individual  differences  may  exist  in  the  induction  of 
liver cell apoptosis by cytotoxic T  cells (and NK cells). Fur- 
thermore, various states of hepatitis exist in which liver cell 
apoptosis  might  be  disregulated,  possibly  involving  the 
CD95 receptor, ligand, or signaling pathway. 
In the present study, we investigated induction of apop- 
tosis in primary human hepatocytes upon CD95  activation. 
Receptor activation by addition of low amounts of agonis- 
tic antibodies to hepatocyte cultures rapidly and efficiently 
killed these cells. Immunohistology of liver tissue from pa- 
tients with chronic HBV infection or acute hepatic failure 
showed highly elevated CD95 receptor expression in hepa- 
tocytes relative to  normal livers.  In situ hybridization de- 
tected CD95L  messenger RNA  (mRNA)  in lymphocytes 
in HBV-related and acute liver damage. It is interesting to 
note that, in alcoholic cirrhosis, high ligand mlKNA levels 
were found in hepatocytes directly. 
Materials  and Methods 
Primary Human Hepatocyte Cultures.  Primary human liver cells 
were prepared from healthy liver tissue  obtained during hepatic 
surgery. The study was approved by the Ethics Committee of the 
Medical  Faculty of the  University of Heidelberg (Heidelberg, 
Germany). Cells were isolated as described (32,  33).  Briefly, the 
resected piece of liver was perfused via a central vessel, first with 
S-MEM  (GIBCO BRL,  Paisley, Scotland) for  10--15  min,  and 
then with Williams' medium E  (WME; GIBCO BILL) contain- 
ing 0.05%  collagenase (Sigma Chemical Co., Munich, Germany) 
and 5 mmol/liter calcium for another 10-15 min. Subsequently, 
nonperfused parts were discarded, and the cell suspension was fil- 
tered  through  gauze,  washed  four  times  with  ice-cold WME 
containing 5% FCS (Sigma Chemical Co.) by differential centri- 
fugation, and seeded in maintenance medium at a density of 1 ￿ 
10 s  viable  cells/cm  2  on  collagen-coated  tissue  culture  dishes 
(Costar  Corp.,  Cambridge,  MA).  Viability was  determined by 
trypan blue dye exclusion (34).  The medium was changed 0.5 h 
after plating and every 1-2 d thereafter. For seeding and mainte- 
nance of cells, WME was used, supplemented with 0.066 Ixmol/ 
liter  insulin  (Serva  Biochemicals,  Heidelberg,  Gemaany),  0.1 
Ixmol/liter glucagon (Eli Lilly, Giessen, Germany), 0.1  Ixmol/li- 
ter triiodothyronine (Serva Biochemicals), 5 mmol/liter glutamine 
(Flow Laboratories GmbH, Meckenheim,  Germany), 37  Ixmol/ 
liter inosine (Serva  Biochemicals), 10  Ixg/ml gentamycin (Flow 
Laboratories GmbH),  100  Ixg/ml streptomycin (Flow Laborato- 
ries  GmbH),  100  Ixg/ml penicillin (Flow Laboratories GmbH) 
and 20 mmol/liter Hepes (Flow Laboratories GmbH).  Cultures 
were incubated at 37~  in 5% CO 2 in air. 
To investigate the capability of human hepatocytes to undergo 
apoptosis upon CD95 stimulation, cells were treated 12 or 48 h 
after plating with the mAb anti-APO-1 (IgG3-containing hybri- 
doma supernatant) at concentrations of 1,  10, 20, or 100 ng/ml. 
Unless otherwise indicated, 20 ng/ml was used. This antibody has 
been shown to induce apoptosis in CD95 antigen-expressing cells 
by receptor cross-linking (15,  35).  Control cultures were treated 
with an mAb at the same concentrations recognizing an influenza 
viral epitope. 
L,'ver Tissues.  All tissues examined in this study were obtained 
from hepatectomy specimens during liver transplantation, imme- 
diately snap frozen in liquid nitrogen and stored at -80~  until 
analyzed. The diagnosis alcoholic cirrhosis was based on histolog- 
ically proven  cirrhosis and  a  daily intake of >60  g  alcohol in 
women and >80 g in men for >10 yr in the absence of serologi- 
cal markers for HBV or hepatitis C virus (HCV). The diagnosis of 
chronic HBV infection was based on a long-standing history of 
chronic hepatitis, the presence of serological markers for HBV, 
and immunohistological detection of hepatitis B surface  Ag and/ 
or hepatitis B core Ag in the liver tissue. 
The criterion used for the diagnosis of acute hepatic failure was 
the development of hepatic encephalopathy within  12 wk from 
the onset of  jaundice in the absence of preexisting liver disease 
(36). Hyperacute liver failure (LF) was assumed in cases in which 
encephalopathy developed within 7 d, acute LF in cases with an 
interval of between 8 and 28 d, and subacute LF in cases with an 
interval of between 5 and 12 wk. The patients with acute hepatic 
failure are listed in Table 1. This group consisted of three patients 
with HCV infection, one with HBV infection, one with hepatitis 
A virus (HAV) infection, and three cases with unknown etiology. 
DAPI Staining and Analysis  of DNA Fragmentation.  For  DAPI 
(4',6-diamidino-2-phenylindole; Sigma Chemical  Co.)  staining 
of DNA, cells were plated on plastic coverslips. After removal of 
the  culture  medium,  cells  were  briefly dipped twice  into  PBS 
Table  1.  Cases with Acute Liver Failure 
Case  Etiology*  Course 
1  HCV  Subacute LF 
2  :  Subacute LF 
3  HCV  Subacute LF 
4  HAV  Hyperacute LF 
5  HCV  Subacute LF 
6  ~  Hyperacute LF 
7  HBV  Acute LF 
8  ~  Acute LF 
1 Abbreviations used in this paper: CD95L, CD95 hgand; HAV, hepatitis A 
virus; HBV, hepatitis B virus; HCV, hepatitis C virus; LF, liver failure; 
mlKNA, messenger RNA; WME, Williams' medium E. 
*As detected by HCV, HCV FkNA in liver tissue; HAV, anti-HAV 
lgM in the absence of other viral markers; HBV, hepatitis B surface Ag 
and hepatitis B core Ag in liver tissue; ?, unknown  etiology. 
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in methanol for 10 n'fin at -20~  followed by acetone for 5 rain 
at  -20~  and air dried.  Staining with DAPI was performed ac- 
cording to the protocol of the manufacturer. 
For DNA electrophoresis,  "-'7 ￿  106 detached cells were har- 
vested after  7.5 h  of treatment with 20 ng/ml anti-APO-1 and 
washed twice in PBS, and DNA was extracted as described  (37). 
Electrophoresis was carried out in a 2% agarose  gel,  and the gel 
was subsequently stained with ethidium bromide. 
Immunohistochemistry.  CD95 antigen detection was performed 
using a monoclonal IgG  1 antibody directed against  CD95  (35). 
The avidin-biotin peroxidase method was applied.  Cryosections 
(4-5 ~m thick) were fixed immediately after sectioning for 5 rain 
in cold acetone, air dried overnight, and either used directly for 
immunolabeling or stored at -80~  until used. Fixed and, in case 
of storage,  thawed sections  were washed in PBS. Sections  were 
then  preincubated  with  streptavidin  and  biotin  for  15  rain  to 
block  endogenous  liver  avidin  (Avidin  Biotin  Blocking  Kit; 
Genex,  Gaithersburg,  MD).  After another  wash,  sections  were 
incubated for 60 min at room temperature with the primary mAb 
at a concentration of 10 I*g/ml. Bound mAbs were visualized by 
the avidin-biotin peroxidase  method using VECTASTAIN Elite 
Kit  (Vector  Laboratories,  Inc.,  Burlingame,  CA)  and  amino- 
ethylcarbazol  as  chromogen.  Counterstaining  was  performed 
with hemalaun. 
The liver  tissues were graded as follows:  0, absence  of CD95 
expression;  1, low constitutive CD95 expression  (28); 2, interme- 
diate CD95 expression;  3, high CD95 expression. 
RNA In Situ Hybridization.  Cryosections (5  txm thick)  were 
prepared from human liver tissues that had been stored at -80~ 
since explantation.  Sections were transferred  onto siliconized  glass 
slides and fixed  in 4% (wt/vol) paraformaldehyde/PBS (20 rain, 
room temperature),  and then briefly washed in PBS (room tem- 
perature)  and dehydrated by sequential  transfer  through 70 and 
95% ethanol baths.  The in situ hybridization procedure was per- 
formed essentially  as described  by Bosch et al.  (38) using an in 
vitro-synthesized,  35S-labeled antisense  RNA  corresponding to 
the  sequence  coding for  amino  acids  100-246  of the  human 
CD95L (39). Controls for the specificity of the ligand signal were 
performed by parallel  treatment  of cryosections with  a  20-fold 
molar excess of unlabeled,  competitor antisense  R.NA.  This re- 
sulted  in a marked reduction in the strength of ligand  signals in 
expressing  cells. In  situ  hybridizations were  dipped  into  liquid 
film emulsion  (K5;  llford Ltd., Basildon,  UK)  and  exposed for 
3-4 wk.  Development of the slides was performed according to 
the instructions  of the manufacturer.  The developed in situ  hy- 
bridizations  were counterstained with hematoxylin and eosin and 
were prepared for microscopy. 
Results 
Induction of Apoptosis  by Anti-Apo- I,  Initial  experiments 
were aimed at determining the sensitivity of human hepa- 
tocytes to the induction of apoptosis by the agonistic anti- 
body anti-APO-1.  Freshly plated cells were treated with  1, 
10,  20,  or  100 ng/ml anti-APO-1.  Control cultures  were 
treated  with  an irrelevant  antibody directed  against an in- 
fluenza viral epitope.  Treatment  for r  h  with  concen- 
trations  of 10  ng/ml  or  above  resulted  in  extensive  cell 
death  (>95%)  as  exemplified  in  Fig.  1  b  for  20  ng/ml. 
Control  cultures  remained  unaffected  (Fig.  1  a).  The  first 
morphological  changes  were  noted  after  4-4.5  h,  when 
cells  became  round  in  shape,  started  to lose  contact  with 
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Figure 1.  Primary human hepatocytes treated with a control antibody 
(a) or with 20 ng/ml anti-APO-I (b) for 7.5 h. Phase contrast, )<160. 
The inset in b shows a rounded-up hepatocyte with cytoplasmic  blebs af- 
ter 5 h of treatment at 360-fold magnification. 
neighboring cells,  and formed cytoplasmic  "btebs"  (Fig.  1 
b,  inset).  These  changes were pronounced after  5.5  h,  and 
after  7.5  h  essentially  all  cells  were  dead  and  mostly  de- 
tached (Fig.  1 b). 
A  quantification  of the  anti-APO-1  effect  using  liver 
cells  12 h  after plating is shown in Fig. 2 a. Nearly all hepa- 
tocytes died within  a short period of 4-7.5 h  after the be- 
ginning of the antibody treatment.  In contrast, control cul- 
tures maintained 90% viability throughout the entire culture 
period.  Treatment  with anti-APO-1  48 h  after plating re- 
sulted  in  similar kinetics  of death but affected only ~60% 
of the  cells  (Fig.  2  b).  This  demonstrates  a  loss in  respon- 
siveness  to CD95  stimulation  with  time  in  culture,  which 
might reflect the loss of differentiated characteristics typically 
encountered in aging liver cells in primary culture (40). 
To  investigate  nuclear  morphology,  DAPI  staining  of 
cellular DNA was performed.  Control cultures maintained 
their  nuclear  morphology  throughout  the  culture  period 
(Fig.  3  a).  In  contrast,  anti-APO-1  treatment  resulted  in 
progressive  condensation  and fragmentation  of the  nuclei, 
changes  characteristic  of apoptosis  (Fig.  3  b,  after  5  h  of 
treatment).  Biochemical analysis of chromosomal DNA in 
dead  cells  that  had  detached  from the  culture  plates  after 
7.5  h  of treatment  demonstrated  fragmentation  of DNA, 
yielding  a  typical  "ladder"  pattern  in  agarose  gel  electro- 
phoresis (Fig. 4). 
CD95  Expression  in  Patients  with  Active  Liver  Disease. 
We investigated  CD95  receptor  expression  in liver  tissues 
from patients who underwent liver transplantation.  A panel 
of tissues  derived  from  patients  with  liver  failure  due  to 
chronic HBV infection-related  cirrhosis  (n  =  9),  alcoholic a 
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Figure 2.  Viability  ofhepatocytes in the presence (t) or absence (O) of 
20 ng/ml anti-APO-1.  Treatment was started 12 h (a) or 48 h (b) after 
plating. Viability was assessed morphologically  after trypan blue staining. 
The data represent mean +- SD of three independent wells. 
cirrhosis (n =  13), or acute hepatic failure (n =  8) was ana- 
lyzed by immunohistology. In addition, normal liver tissues 
(n =  5) were examined.  Normal liver and the majority (12 
out of 13) of the cases with alcoholic liver disease showed a 
low constitutive level of CD95  expression  on the hepato- 
cyfic cell membrane,  homogeneously distributed  through- 
out the  liver  sections,  as  exemplified  in  Fig.  5  a  for alco- 
holic  cirrhosis.  In  contrast,  in  patients  with  HBV-related 
cirrhosis  (8/9),  highly up-regulated  CD95  expression  was 
detected on the cell membrane ofhepatocytes (Fig. 5 b). In 
the  eight patients  with acute hepatic  failure,  only small  is- 
lands  of dying hepatocytes surrounded by monocytic cells 
were seen. These islands displayed CD95 expression at high 
levels in all  cases  (Fig.  5  c).  The data on CD95  expression 
levels in the panel of human liver tissues are summarized in 
Table 2. 
CD95L  mRNA  Expression  in  Patients  with  Chronic  and 
Acute Liver Failure.  To  determine  whether  the  CD95L is 
expressed  in  cases  of ongoing liver  damage,  our panel  of 
liver  tissues  was  also  examined  for  expression  of CD95L 
mRNA.  CD95L mRNA  expression was not detectable  in 
normal liver  (zero out of three cases examined).  However, 
easily  detectable  or  high  levels  of CD95L  mRNA  were 
found in livers  with  ongoing cell damage,  h  is interesting 
Figure  3.  DNA staining with DAPI in controls (a) and anti-APO-l- 
treated (b) liver cells after 5 h of  treatment. X400. 
to note  that two different patterns  of expression were dis- 
cerned.  In  cases  with  HBV-related  cirrhosis  (three  out  of 
three),  CD95L  mRNA  expression  was  found  in  the  pe- 
riphery of the pseudolobules at the border to the periportal 
tracts at the side of piecemeal  cell death  (Fig.  6, a and a'). 
Thus,  CD95L mRNA  expression  localizes  to  the  area  of 
lymphocytic infiltration. Similarly, in one out of three cases 
(Table  1,  case  No.  4)  with  virus-induced,  acute  hepatic 
failure, ligand mRNA  expression was detected in lympho- 
cytes surrounding islands of dying hepatocytes (not shown). 
In the other two cases with acute LF examined for CD95L 
expression,  the  tissue  destruction  was  too  advanced  for 
morphological  analysis.  In  contrast  to  this  picture,  in  the 
cases  of alcoholic  cirrhosis  (three  out of three),  very high 
CD95L  mRNA  expression  was  detected  in  the  center  of 
the cirrhotic pseudolobnle (Fig. 6, b and b '). Thus, CD95L 
mRNA  was mainly found in areas where  no lymphocytes 
but  only  hepatocytes  and  mesenchymal  liver  cells  (i.e., 
Figure  4.  Agarose gel  electrophoresis 
of cellular DNA from hepatocytes after 
7.5  h  of treatment  with anti-APO-1 
(right) or a control antibody (/eft). 
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CD95 receptor 
Liver tissue of  n  expression* 
Normal liver  5  0.8 
Alcoholic cirrhosis  13  1.15 
HBV-related cirrhosis  9  2.45 
Acute liver failure  8  2.5 
This table gives the mean on the basis of  the immunohistological grad- 
ing of the human liver tissues as outlined in Materials and Methods. 
The SE was always <0.4. 
* Score for immunohistology: 0, no expression; 1, weak expression; 2, 
intermediate expression; 3, high expression. 
their large round nuclei localized centrally within  a  broad 
cytoplasm. 
Figure 5.  CD95 receptor expression in livers with chronic fiver disease 
and hver failure. (a) Alcoholic cirrhosis with faint expression of CD95 on 
the membranes ofhepatocytes. The black dots indicate unspecific staining 
of bile in  this cholestatic cirrhosis. (b)  Cirrhosis with chronic HBV- 
induced hepatitis. Shown is the strong expression of  CD95 antigen on the 
membrane of hepatocytes, accentuated at sites of inflammation and con- 
tact with infiltrating lymphocytes. (c) Subacute, cryptogenic liver failure 
(case No. 2 in Table 1). Only few intact hepatocytes are visible with 
marked expression of  CD95 antigen on their cell membranes. Some infil- 
trating lymphocytes  also show CD95 antigen expression. ￿  180. 
Kupffer  cells  and  endothelial  cells)  are  present.  This  was 
confirmed by investigation ofhematoxylin and eosin-stained 
parallel sections (not shown). This finding strongly suggests 
that  the  CD95L  can be  expressed  in hepatocytes.  Indeed, 
higher magnification revealed  the presence  of silver grains 
in  hepatocytes  (Fig.  6  c),  as  morphologically identified  by 
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Discussion 
This paper demonstrates that triggering of the CD95 re- 
ceptor by agonistic anti-APO-1  antibodies  rapidly induces 
massive apoptotic cell death in primary human hepatocytes. 
This finding in human hepatocytes reflects the acute sensi- 
tivity of the liver to CD95 stimulation previously observed 
in  the  mouse  in vivo  (29)  and  in  vitro  (41),  and  it shows 
that constitutive receptor expression levels are functionally 
sufficient for CD95-mediated apoptosis. 
These  observations  raise  the  question  of whether  liver 
damage in humans  in vivo is  mediated  by the  CD95  sys- 
tem.  In  this  context,  we  examined  explanted  liver  tissues 
from patients  with  normal  livers,  HBV-rdated  and  alco- 
holic cirrhosis,  and acute liver failure.  Our results  confirm 
the observation of constitutive low expression of CD95 in 
normal human liver (28). In contrast, in livers from patients 
with  chronic  HBV  infection  or acute  hepatic  failure  but 
not with alcoholic cirrhosis, CD95 receptor expression was 
found  to  be  up-regulated.  Increased  CD95  expression  as 
observed in livers  with  ongoing cell  damage in  this  study 
may have several implications.  Enhanced receptor  expres- 
sion might initiate the disease. Alternatively, CD95 expres- 
sion might be increased  in  response  to  a primary stimulus 
and  render  the  hepatocyte  more  susceptible  to  CD95L 
stimulation.  This  assumption  is supported by the  observa- 
tion that induction of CD95 expression occurs as a result of 
chronic,  lymphohistiocytic  inflammation  in  different  epi- 
thelial cells (28). 
To assess CD95L synthesis and to define the ligand-pro- 
ducing effector cell,  mP,  NA in situ hybridization was per- 
formed.  In patients  with  chronic  HBV infection,  CD95L 
mRNA  was found to be  expressed  in areas with lympho- 
cytic infiltration,  in contrast to normal liver,  where no sig- 
nal was detectable.  In vitro evidence exists that activated T 
cells  express  the  CD95L.  In addition,  the  CD95  pathway 
constitutes  a  major  mechanism  of T  cell-mediated  cyto- 
toxicity  (10,  20,  21,  27,  42-45).  Moreover,  expression  of Figure 6.  CD95L mRNA expression in chronic liver disease. (a) Dark field; (a ') bright field view of an HBV-related cirrhosis  with chronic hepatitis. A 
cirrhotic nodule (CN) is shown surrounded by a dense inflammatory infiltrate. A prominent ligand signal is detectable at the border (arrows) of the same 
cirrhotic nodule in dark field view. (b) Dark field; (b') bright field view of an alcoholic cirrhosis. A cirrhotic nodule (CN) is surrounded by fibrous bands 
and fibrotic portal tracts (arrows). The silver grain signal in the dark field view is found in the center of  the same cirrhotic nodule. (c) Higher magnification 
orb' with evidence of CD95L mP,  NA within a hepatocyte. (a, a', b, and b') ￿  (c) ￿ 
the  CD95L  has  been  shown  recently for  liver-infiltrating 
mononuclear cells in patients with hepatitis C  (46). There- 
fore, activated T-killer cells may kill HBV-infected hepato- 
cytes using the CD95 system. A  different degree of CD95- 
mediated  cytotoxicity  may  account  for  various  disease 
stages.  Such  different  levels  of cytotoxicity  may  explain 
ineffective viral clearance in chronic hepatitis, regular clear- 
ance in acute, self-limiting hepatitis, or over-effective clear- 
ance in gflminant hepatitis. Indeed, in chronic HBV-induced 
liver failure, a poor response to HBV antigens has been de- 
scribed for MHC  class I- and II-restricted T  cells (47). 
Unexpectedly, in alcoholic hepatitis, the CD95L was ex- 
pressed at high levels in hepatocytes directly. The presence 
of ligand mRNA  and receptor in the same cell points to a 
new mechanism of liver cell damage. Initial investigation of 
ligand expression in the rat revealed that the CD95L is not 
expressed in the liver (20).  However, our data demonstrate 
that,  in  alcoholic liver damage,  human  hepatocytes them- 
selves  can  up-regulate  the  CD95  system.  The  CD95L 
might be expressed as a membrane-bound form and might 
mediate apoptosis as "fratricide" interacting with the CD95 
receptor on neighboring cells. Alternatively, CD95-medi- 
ated apoptosis may occur in an autocrine or paracrine fash- 
ion via a soluble form of the ligand. Indeed, soluble ligand 
activity capable of inducing apoptosis has been detected in 
supernatants of anti-CD3-stimulated T  cells (43).  Our data 
show  that  the  above forms  of CD95-mediated  killing are 
not  restricted to lymphocytes but may also occur in  non- 
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ceivable that the CD95  system is highly relevant for apop- 
tosis of various tissues throughout the body. 
The involvement of the CD95  pathway in hepatocellu- 
lar damage offers a  new fundamental understanding of de- 
structive liver disease, particularly in alcoholic cirrhosis, and 
it may provide new therapeutic approaches based on inter- 
ference with CD95  receptor-ligand interaction or with the 
signaling pathway. 
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